Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MedMira Inc MMIRF


Primary Symbol: V.MIR

MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.


TSXV:MIR - Post by User

<< Previous
Bullboard Posts
Next >>
Post by august202013on Jun 13, 2023 2:30pm
176 Views
Post# 35494264

3RD QUARTERLY FINANCIALS ENDING 30-04-2023 SHOULD BE READY !

3RD QUARTERLY FINANCIALS ENDING 30-04-2023 SHOULD BE READY !BY NOW THE 3RD QUARTERLY FINANCIALS ENDING. APRIL, 30, 2023  ARE ALREADY READY WITH MM PENDING RELEASE BY FIRST WEEK OF JULY, 2023 BUT COULD BE WELL BEFORE JULY, 7, 2023.

HAVE TO BE PATIENT AND WAIT FOR THE RELEASE AND FACE WHAT EVER COMES OUT. NO MIRACLE EXPECTED AS THERE WAS NO HUGE DEMAND FOR COVID19 TEST KIT EVEN IN EUROPE FOR PERIOD FEBRUARY/MARCH/APRIL 2023. AS HAVE TO BE REALISTIC. ANY SUPRISES WOULD BE FROM REVEAL TP (SYPHILIS) WITH CE MARK IN EUROPE IN EARLY MARCH 2023 AND CLINICAL TRIAL IN SACHKETCHWEN  ALSO CONDUCTED IN BC IN APRIL, 2023.  AS SUCH COULD INCLUDE 2 MONTHS SALES FIGURE FROM THAT LINE.

HOPING FOR A SLIGHT DEFICIT WILL BE A PLUS MAYBE A GOOD BUY NOW PENDING FINANCIAL RELEASE BUT A HUGE DEFICIT WILL BE SOMBER MOOD AND HAVE TO BRACE FOR BIGGER DEFICIT FOR 4TH QUARTERLY UNLESS HC ISSUES A PO WHICH SHOULD THEN BE A BUY, 

MILLION DOLLAR QUESTION IS

IF HC (NOT BIG BROTHER) IS GOING TO?

LIKELIHOOD ?  

ANSWER IS BETTER THIS ROUND
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse